MyOme uses whole-genome sequencing and state-of-the-art bioinformatics to analyze patient DNA and produce comprehensive and clinically actionable reports that allow patients and their providers to make personalized lifestyle, prevention, and treatment choices.
Our tests
Accurate, comprehensive, actionable testing from a single sample
MyOme provides access to proactive and diagnostic tests that can be ordered by a healthcare provider.
Map personal health risks to guide lifelong proactive health decisions.
MyOme offers comprehensive genomic sequencing that goes beyond limited gene panels, delivering actionable insights for screening, medication decisions, lifestyle adjustments, and diagnostics — all from a single sequence.
Our proprietary integrated polygenic risk scores (iPRS) combine clinical factors and are validated across diverse ancestries including individuals of mixed ancestry, ensuring the most personalized and precise risk assessment.
We prioritize data security with uncompromising standards — information is never sold or used without explicit consent.
We make genomic testing and precision medicine more accessible across care settings, including primary care. Our seamless, end-to-end support model integrates effortlessly into busy clinics, reducing the burden on providers and their staff.
We also empower patients with the resources they need to understand and act on their genomic insights. From easy test ordering and actionable reports to clear clinical summaries, education, and optional genetic counseling, we provide comprehensive support for both providers and patients.
Learn how genetics can help inform your health decisions
In my practice in the Philadelphia area, I see patients of diverse ancestries for whom current ASCVD tools do not assess risk equitably or adequately consider other genetic factors for CAD. There are steps someone can take once we accurately identify those at risk, whether it is common medications such as statins, imaging or changes to lifestyle that can reduce heart-related events.
Dr. Dan Rader, MDUPenn Medicine
“
Broad Clinical Labs has always been at the forefront of deploying the most advanced genomic sequencing technologies and together with MyOme's bioinformatics and analysis pipeline, we can bring this power to the clinic, seamlessly providing patients and providers individual risk assessments powered by an individual's whole genome.
Nial Lennon, PhDCSO and Chair, Broad Clinical Labs
“
Communities in Alabama and across the nation have waited too long for advances in healthcare technologies — specifically genetics — to benefit them in clinical practices. Providing these patients and their providers with personalized health insights using MyOme's industry-leading, clinical risk assessments will allow providers to identify potentially life-saving interventions, lifestyle and medication changes, imaging, and early cancer detection tests for their patients.
Josh Carpenter, PhDFormer President and CEO, Southern Research
The latest from MyOme
Blog
Variants of Uncertain Significance (VUS) in Rare Disease: What Every Provider Should Know
.png&w=1536&q=100)
